Can Neuroblastoma Be Cured? A Guide to Prognosis and Treatment

Neuroblastoma is a rare childhood cancer that begins in early nerve cells[^41]. For families facing this diagnosis, the most urgent question is: can it be cured?2 The answer is often yes, but the path to a cure is different for every child. The curability of neuroblastoma depends entirely on a unique set of factors, including the child’s age, the cancer's genetic makeup, and how far it has spread.

This cancer develops from immature nerve cells called neuroblasts, part of the sympathetic nervous system which controls functions like heart rate and blood pressure[^53]. These neuroblasts are left over from a baby's development in the womb4. While they normally mature or disappear, in neuroblastoma they grow uncontrollably into a tumor4. Because these cells are found throughout the body, tumors can appear in the adrenal glands (on top of the kidneys), neck, chest, abdomen, or pelvis3. Understanding the specific characteristics of a child's tumor is the first and most critical step in creating a successful treatment plan2.

Diagnosis and Determining Risk

Because neuroblastoma behaves so differently from one child to another, a precise diagnosis is the critical first step in determining whether it can be cured. This process involves not just confirming the cancer's presence, but understanding its specific risk profile, which guides every treatment decision2.

Key Diagnostic Steps

The diagnostic journey begins with simple tests and advanced imaging. Doctors test blood and urine for specific substances, called catecholamines, that are produced by neuroblastoma cells; high levels can be a strong indicator of the disease4. At the same time, imaging scans like an ultrasound, CT, or MRI provide a detailed picture of the primary tumor’s size and location.

To confirm the diagnosis and see if the cancer has spread, a surgeon performs a biopsy to remove a small piece of the tumor for examination2. A pathologist studies the tissue to identify cancer cells and assess their aggressiveness2. To check for spread (metastasis), doctors use a specialized MIBG scan, where a safe radioactive tracer is absorbed by neuroblastoma cells, lighting them up anywhere in the body. A bone marrow biopsy is also essential, as marrow is a common site of metastasis.

How Risk Is Determined

All the diagnostic data is combined to classify the neuroblastoma into a low-, intermediate-, or high-risk group4. This risk level, more than any other single factor, predicts the cancer's behavior and determines the intensity of treatment needed4.

• Child's Age at Diagnosis: Age is a powerful predictor4. Infants diagnosed under 12 to 18 months have a much better prognosis, even if the cancer has spread. Neuroblastoma in very young children often has a more favorable biology and can sometimes even regress on its own with minimal or no treatment. In older children, the disease tends to be more aggressive3.

• Tumor Genetics (The MYCN Gene): The tumor's genetic signature is crucial. The most important marker is the MYCN gene. If the tumor cells have extra copies of this gene—a condition called MYCN amplification—the cancer is almost always classified as high-risk. This genetic feature acts as an accelerator, driving the cancer to grow and spread rapidly, making it more resistant to standard therapies.

• Cancer Stage and Histology: The cancer’s stage (how far it has spread) and its appearance under the microscope (known as its histology) are also key3. Localized tumors that have not spread are easier to treat and have a higher cure rate1. Cancers that have metastasized to distant sites like the bones, liver, or bone marrow require more intensive, body-wide treatment. Favorable histology means the cells look less aggressive, which points to a better outcome.

How Neuroblastoma Is Treated

With a clear risk classification, doctors can tailor a treatment plan perfectly matched to the child’s disease[^32]. The goal is to provide enough therapy to achieve a cure while minimizing long-term side effects.

Low-Risk Neuroblastoma

For children with low-risk disease, the approach is often gentle3. In many cases, particularly for infants, treatment may consist only of careful observation with regular check-ups, known as "watch-and-wait," as these tumors can shrink and disappear on their own4. If treatment is needed, surgery to remove the tumor is often sufficient1. The prognosis for this group is excellent, with survival rates well over 95%3.

Intermediate-Risk Neuroblastoma

This group requires a more active approach, as the tumors are unlikely to resolve without intervention but are not as aggressive as high-risk disease4. Treatment typically involves a moderate course of chemotherapy to shrink the tumor, followed by surgery to remove it. The therapy is carefully balanced to control the cancer effectively. This strategy leads to very high cure rates, generally between 90% and 95%.

High-Risk Neuroblastoma

High-risk neuroblastoma presents the greatest challenge and requires a complex, multi-stage treatment plan that can last more than a year. The journey is intensive and includes:

1. Induction Chemotherapy: Strong chemotherapy to attack cancer throughout the body.
2. Surgery: To remove the primary tumor1.
3. High-Dose Chemotherapy with Stem Cell Transplant: An extremely powerful dose of chemotherapy to eliminate any remaining cancer, followed by an infusion of the child's own previously collected stem cells to rebuild the bone marrow.
4. Radiation Therapy: To target the original tumor site and any other areas of disease.
5. Immunotherapy: The final phase uses drugs that help the child’s own immune system find and destroy any last cancer cells.

While this aggressive therapy has dramatically improved outcomes, the cure rate for high-risk disease is currently around 50% to 60%, making it the primary focus of ongoing research.

The Future of Treatment: Emerging Therapies

The world of neuroblastoma research is active and focused on finding better, gentler treatments, especially for high-risk and relapsed disease2. Several promising new approaches are being explored in clinical trials2.

Targeted Therapies

Instead of traditional chemotherapy, which affects all fast-growing cells, researchers are developing "smart drugs" that attack specific weaknesses in neuroblastoma cells2. For example, some relapsed tumors have a mutation in the ALK gene4. New ALK inhibitors can block the signals from this faulty gene, stopping the cancer's growth with potentially fewer side effects4.

Next-Generation Immunotherapies

Building on the success of current immunotherapy, scientists are engineering more powerful ways to weaponize a child's immune system2. CAR T-cell therapy is a leading example2. A child's immune cells (T-cells) are removed, genetically modified in a lab to recognize neuroblastoma cells, and then infused back into the patient2. These engineered cells become a "living medicine," actively hunting and destroying cancer2.

Radioisotope Therapy

This clever approach uses a molecule that neuroblastoma cells naturally absorb to deliver radiation directly to the cancer2. In MIBG therapy, a high, therapeutic dose of radioactive iodine is attached to the MIBG molecule2. When infused, it is taken up almost exclusively by neuroblastoma cells, delivering targeted radiation from the inside out while largely sparing healthy tissue2. This is especially useful for treating widespread disease in the bones and bone marrow2.

#neuroblastoma